Hyperfibrinogenemia	O
is	O
associated	O
with	O
lymphatic	B-Multi-tissue_structure
as	O
well	O
as	O
hematogenous	O
metastasis	O
and	O
worse	O
clinical	O
outcome	O
in	O
T2	B-Cancer
gastric	I-Cancer
cancer	I-Cancer
.	O

BACKGROUND	O
:	O
Abnormal	O
hemostasis	O
in	O
cancer	B-Cancer
patients	O
has	O
previously	O
been	O
described	O
,	O
however	O
the	O
correlation	O
between	O
the	O
plasma	B-Organism_substance
fibrinogen	O
level	O
and	O
cancer	B-Cancer
metastasis	O
and	O
prognosis	O
has	O
not	O
been	O
reported	O
in	O
a	O
large	O
-	O
scale	O
clinical	O
study	O
.	O

METHODS	O
:	O
Preoperative	O
plasma	B-Organism_substance
fibrinogen	O
levels	O
were	O
retrospectively	O
examined	O
in	O
405	O
patients	O
who	O
underwent	O
surgery	O
for	O
advanced	O
gastric	B-Cancer
cancer	I-Cancer
.	O

The	O
association	O
of	O
fibrinogen	O
levels	O
with	O
clinical	O
/	O
pathological	O
findings	O
and	O
clinical	O
outcome	O
was	O
evaluated	O
.	O

RESULTS	O
:	O
There	O
was	O
a	O
positive	O
correlation	O
between	O
plasma	B-Organism_substance
fibrinogen	O
levels	O
and	O
the	O
depth	O
of	O
invasion	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Hyperfibrinogenemia	O
(	O
>	O
310	O
mg	O
/	O
dl	O
)	O
was	O
independently	O
associated	O
with	O
lymph	B-Multi-tissue_structure
node	I-Multi-tissue_structure
(	O
Odds	O
Ratio	O
;	O
2	O
.	O
342	O
,	O
P	O
=	O
0	O
.	O
0032	O
)	O
and	O
liver	B-Organ
(	O
Odds	O
Ratio	O
;	O
2	O
.	O
933	O
,	O
P	O
=	O
0	O
.	O
0147	O
)	O
metastasis	O
,	O
not	O
with	O
peritoneal	B-Multi-tissue_structure
metastasis	O
in	O
this	O
series	O
.	O

Patients	O
with	O
hyperfibrinogenemia	O
showed	O
worse	O
clinical	O
outcome	O
in	O
T2	B-Cancer
gastric	I-Cancer
cancer	I-Cancer
,	O
however	O
,	O
there	O
was	O
no	O
correlation	O
of	O
plasma	B-Organism_substance
fibrinogen	O
level	O
with	O
prognosis	O
in	O
T3	B-Cancer
/	I-Cancer
T4	I-Cancer
gastric	I-Cancer
cancer	I-Cancer
.	O

CONCLUSION	O
:	O
Our	O
results	O
might	O
support	O
the	O
idea	O
that	O
hyperfibrinogenemia	O
can	O
augment	O
lymphatic	B-Cell
and	O
hematogeneous	O
metastasis	O
of	O
advanced	O
gastric	B-Cancer
cancer	I-Cancer
,	O
which	O
is	O
major	O
determinant	O
of	O
the	O
prognosis	O
in	O
T2	B-Cancer
gastric	I-Cancer
cancer	I-Cancer
.	O

Therefore	O
,	O
in	O
the	O
situation	O
without	O
peritoneal	B-Multi-tissue_structure
involvement	O
,	O
hyperfibrinogenemia	O
is	O
a	O
useful	O
biomarker	O
to	O
predict	O
the	O
possible	O
metastasis	O
and	O
worse	O
clinical	O
outcome	O
in	O
T2	B-Cancer
gastric	I-Cancer
cancer	I-Cancer
.	O

